The first annual report of GLS is out this week and an interesting piece of information that was buried in the AR was the following list. It has the products that were developed & validated in the current fiscal. One can assume that these are ready to commercialize or already have been commercialized.
I’ve given their global sales and originator company name to give readers/investors a sense of the opportunity at hand.
| Sr.No. | Generic | Brand | Originator | Size ($mil) |
|---|---|---|---|---|
| 1 | Briviracetam | Briviact | UCB | $355.00 |
| 2 | Bilastine | – | FAES Farma | $290.00 |
| 3 | Elagolix Sodium | Orilissa | AbbVie | $39.00 |
| 4 | Edoxaban Tosylate | Savaysa | Daiichi Sankyo | $563.00 |
| 5 | Hydralazine HCL | Apresoline | Hikma | $51.00 |
| 6 | Iron Sucrose | Venofer | Vifor | $146.00 |
| 7 | Tafamidis Meglumine | Vyndamax | Pfizer | $561.00 |
| 8 | Verapamil HCL | – | $28.00 | |
| 9 | Labetalol – CDMO | – | Hikma | $6.00 |
| Total → | $2,039.00 |
| Subscribe To Our Free Newsletter |
